26th July 2012 - News release


A new class of drug is being developed at Northwestern University as a single therapy for Alzheimerís Disease, Parkinsonís Disease, Multiple Sclerosis and traumatic brain injury by reducing inflammation in the brain. Northwestern University has been issued patents to cover this new drug class and has licensed the commercial development to a biotech company that has recently completed the first human Phase 1 clinical trial for the drug. The drugs in this class, represented by MW151 and MW189, target a particular type of brain inflammation, which they claim is a common denominator in these neurological disorders, as well as in traumatic brain injury and stroke. They claim that brain inflammation plays a major role in the progressive damage characteristic of these chronic diseases and brain injuries. For more information, go to the News release.

Despite their claims, there is no evidence that inflammation is a primary cause of Parkinson's Disease. Parkinson's Disease has been shown to be due to the insufficient formation of dopamine, which is completely unaccounted for by this method. Their recent study solely concerned Alzheimer's Disease in mice who did not even have Alzheimer's Disease, and was not shown to rid or reduce Alzheimer's Disease. They have not obtained any evidence at all concerning efficacy in Parkinson's Disease. For a printable version of this article click here For more current news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

















Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports



©2006-2013  Viartis
2015-09-03 13:15:12
[email protected]